A Pilot Study of Oxaloacetate in Subjects With Treated PD

A Pilot Double-Blind, Parallel Group, Placebo Controlled Study of Oxaloacetate in Subjects With Treated Parkinson's Disease (PD)

The purpose of this study is to determine if Oxaloacetate (OAA) is a safe and effective treatment for Parkinson's disease. Each subject will be asked to make 3 study visits and complete two safety follow-up phone calls over a 4 month period.

Inclusion Criteria:

• Able to give informed consent and follow instructions per the protocol
• Diagnosis of idiopathic PD within 7 years of diagnosis
• Taking stable doses of levodopa and would not predictably need adjustment in PD medications for 4 months
• Unified Parkinson's Disease Rating Scale (UPDRS) II + III at least 30 points at baseline

Exclusion Criteria:

• Previously taken Oxaloacetate
• Participation in other drug studies or use of other investigational products within 30 days prior to baseline
• In the Investigator's opinion, any unstable or clinically significant condition that would impair the subjects' ability to comply with study follow-up
• Other known or suspected cause of parkinsonism